Taconic Biosciences Expands Microbiome Portfolio
4.5.2017 21:57 | NASDAQ OMX
Germ Free BALB/c Mice Facilitate Discovery of New Therapeutics
HUDSON, N.Y., May 04, 2017 (GLOBE NEWSWIRE) -- Taconic Biosciences, global leader in genetically engineered mouse models and associated services and the only commercial provider of germ-free mice, announced it has added Germ Free BALB/c mice to its microbiome portfolio. The new product expands Taconic's existing collection of germ-free animal models, which includes C57BL/6 (Black 6) and Swiss Webster mice.
The BALB/c inbred strain is commonly used for antibody production and vaccine efficacy studies. It is also widely used in adoptive transfer studies such as adoptive transfer colitis models and syngeneic tumor studies for immuno-oncology research. Taconic offers Germ Free BALB/c mice as an off-the-shelf product, with study cohorts available for immediate worldwide delivery.
"BALB/c have been an unmet need in terms of germ-free strain availability," said Dr. Alexander Maue, Taconic's portfolio director for microbiome products and services. "The BALB/c inbred strain displays Th2-biased immune responses, as opposed to the Th1 bias in C57BL/6 mice, opening a whole new range of studies. Availability of germ-free mice in quantities relevant for drug discovery accelerates development of microbiome-focused therapeutics."
Germ-free mice, also referred to as axenic mice, contain no microflora. These mice can be associated with specific human or mouse flora, or mono-associated with particular bacteria. Germ-free mice are the ideal substrate for performing fecal microbiota transplants (FMT), a service provided by Taconic. Following FMT, Taconic also offers husbandry services to accommodate studies of all sizes and lengths including options for isolators and state-of-the-art individually ventilated cages (IVCs).
Study of the microbiome has become a prime focus of drug discovery, as evidence mounts demonstrating the connection between a person's flora and their health. Science magazine named the microbiome their breakthrough of the year in both 2011 and 2013 and the microbiome topped Cleveland Clinic's medical innovations list for 2016. Taconic's microbiome platform provides key products and services to study this connection.
To learn more about Taconic's microbiome solutions, visit Taconic.com/microbiome or contact us at 1-888-TACONIC (888-822-6642) in the US, +45 70 23 04 05 in Europe, or at firstname.lastname@example.org.
About Taconic Biosciences, Inc.
Taconic Biosciences is a fully-licensed, global leader in genetically engineered rodent models and services. Founded in 1952, Taconic helps biotechnology companies and institutions acquire, custom generate, breed, precondition, test, and distribute valuable research models worldwide. Specialists in genetically engineered mouse and rat models, precision research mouse models, and integrated model design and breeding services, Taconic operates three service laboratories and six breeding facilities in the U.S. and Europe, maintains distributor relationships in Asia and has global shipping capabilities to provide animal models almost anywhere in the world.
Kelly Owen Grover
Director of Marketing Communications
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Taconic Biosciences via Globenewswire
Följ NASDAQ OMX
Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.
Senaste nyheterna från NASDAQ OMX
Oxford Immunotec Appoints Richard Wenstrup, MD, as Chief Medical Officer24.7.2017 15:00 | Pressmeddelande
OXFORD, United Kingdom and MARLBOROUGH, Mass., July 24, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced the appointment of Richard Wenstrup, MD, as Chief Medical Officer. Dr. Wenstrup brings to Oxford Immunotec more than 20 years of clinical leadership experience, including over a decade within the diagnostics industry. Most recently, Dr. Wenstrup served as Executive Vice President, Chief Medical Officer, for Myriad Genetics, Inc., where he played a key leadership role and made substantial contributions across the company that helped drive and support a multi-fold increase in revenue over a decade. In addition to building and leading Myriad's clinical and medical affairs teams, Dr. Wenstrup was actively involved in the company's product development, M&A, and in-licensing activi
Minerva Neurosciences Announces Departure of Directors24.7.2017 14:30 | Pressmeddelande
WALTHAM, Mass., July 24, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the resignation of two members of its board of directors, Michele Ollier and Nico Vandervelpen. Following the Company's recent public offering and the resultant improvement in its financial position, Dr. Ollier and Mr. Vandervelpen will step down to focus on their private equity activities. Their resignations are effective today. "We would like to thank Michele and Nico for their invaluable contributions to Minerva as a private company and as it has transitioned during the past three years from a venture capital-backed company to a publicly traded company that has advanced several assets into late-stage clinical development," said Marc Beer, chairman of Minerva. About Minerva Neurosciences
French Energy Operator GRDF Enlists Appian's Low-code Platform for Enterprise-wide Deployment24.7.2017 14:00 | Pressmeddelande
RESTON, Va., July 24, 2017 (GLOBE NEWSWIRE) -- Appian (NASDAQ:APPN) today announces that leading French gas distributor GRDF will deploy its latest enterprise application developed on Appian's low-code platform. The new application is designed to manage the extension of gas distribution networks in France, and will be deployed to more than 2,500 users across GRDF. This marks GRDF's fifth major application deployed on the Appian Platform. GRDF is already benefitting from Appian's low-code applications, which enhance the customer experience and transform traditional business methods to more efficient and agile processes. Appian provides GRDF with the speed needed to capitalize on opportunities that the digital world presents, as well as the power to streamline complex business processes. Jean-Marc Wojtecki, Deputy CIO at GRDF, commented: "We solidly believe in the power of low-code for building new applications quickly. Appian allows us to innovate more effici
Placetel is named as a leading UC solution in Germany by ISG Experton Group24.7.2017 10:00 | Pressmeddelande
Placetel, Powered by BroadSoft, named as a leader in the "ISG Provider Lens Germany 2017 - Cloud Transformation / Operation Services & XaaS" Study recognizes broad functional spectrum and strong focus on SMEs Operation of data centers in Germany is acknowledged as a further advantage COLOGNE, Germany, July 24, 2017 (GLOBE NEWSWIRE) -- Placetel, a cloud PBX service from BroadSoft Germany GmbH, has been named by ISG/Experton Group, a leading fully integrated research, advisory and consulting company, as one of the best cloud-based solutions for Unified Communications as a Service (UCaaS) in Germany. ISG/Experton Group positioned Placetel, powered by BroadSoft, in the leadership quadrant in its provider comparison "ISG Provider Lens Germany 2017 - Cloud Transformation / Operation Services & XaaS". An infographic accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/Attach
Gaining Momentum: Vricon Hires Barry Tilton as CTO and VP of Engineering21.7.2017 15:21 | Pressmeddelande
McLean, Virginia, July 20, 2017 (GLOBE NEWSWIRE) -- Vricon, a global leader in 3D imagery, is pleased to announce the addition of Barry Tilton, who will join Vricon Systems LLC as the Vice President of Engineering and CTO for U.S. Government Programs. Vricon's mission is to build The Globe in 3D by producing photorealistic 3D products and digital elevation models with unmatched coverage and delivery timelines. Tilton will spearhead efforts to create new content and improve response times and product quality for Vricon's customers. Tilton brings a unique and extensive background in the Defense and Intelligence communities, having worked in remote sensing systems design and user support for a range of customers, to include the Air Force Space program, the National Geospatial-Intelligence Agency, the National Reconnaissance Office, the Office of the Director of Intelligence, and the Under Secretary of Defense for Intelligence. Tilton also has experience in international technic
REG Celebrates Completion of Upgrade Project at Emden Biorefinery20.7.2017 19:46 | Pressmeddelande
EMDEN, Germany, July 20, 2017 (GLOBE NEWSWIRE) -- Renewable Energy Group, Inc. (NASDAQ:REGI) marked the completion of upgrades at its Emden, Germany biorefinery Wednesday with a ribbon cutting ceremony with government and community members. REG invested 2.5 million € for the installation of a new biodiesel distillation column and a thermal oil heater. "This investment is another milestone in REG's European strategy to be a leader in delivering high quality biofuels," said Jean Scemama, Vice President, REG Energy Europe. "Within this strategy, Emden is positioned to perform well with deep water access to receive and deliver products by vessel and can now meet or exceed the highest quality standards required by our customers." "This project is a result of teamwork across REG's teams in Europe and the U.S." said Brad Albin, Vice President, Manufacturing. "Upgrading Emden's distillation capability enables us to more effe
I vårt nyhetsrum kan du läsa de senaste nyheterna, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt nyhetsrum